Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Phase I/II trial of zolucatetide, a direct β-catenin:TCF inhibitor, in desmoid tumors

Robin Jones, MBBS, MRCP, MD, Institute of Cancer Research, London, UK, comments on updated safety and efficacy from a Phase I/II study (NCT05919264) of zolucatetide, a first-in-class peptide that directly inhibits the β-catenin:TCF interaction, in patients with desmoid tumors. Zolucatetide was well tolerated, with mostly low-grade, reversible adverse events and no treatment discontinuations due to toxicity. All evaluable patients achieved disease control, with a high objective response rate and rapid responses. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

This was a Phase One, Phase Two dose escalation, dose optimization trial, and the trial confirmed the optimal induction dose of the drug followed by a maintenance dose as well. The very interesting point about this is that it’s a direct beta-catenin TCF inhibitor and there was a high response rate within the cohorts of the trial which really indicate that this drug is effective and warrants further investigation in desmoid tumors and none of the patients discontinued treatment due to adverse events...

This was a Phase One, Phase Two dose escalation, dose optimization trial, and the trial confirmed the optimal induction dose of the drug followed by a maintenance dose as well. The very interesting point about this is that it’s a direct beta-catenin TCF inhibitor and there was a high response rate within the cohorts of the trial which really indicate that this drug is effective and warrants further investigation in desmoid tumors and none of the patients discontinued treatment due to adverse events. So the drug also has a manageable and good safety profile.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.